Laidlaw analyst Yale Jen lowered the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $68.00 (from $79.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE